



## CLAIMS

1. A compound represented by the formula



wherein Ring A represents an optionally substituted  
 5 pyridine ring, X represents an electron-attracting group, Y  
 represents an optionally substituted divalent C<sub>1-6</sub> chained  
 hydrocarbon group, R<sup>1</sup> represents an optionally substituted  
 hydrocarbon group, and R<sup>2</sup> and R<sup>3</sup> each independently  
 represent a hydrogen atom, an optionally substituted  
 10 hydrocarbon group or an optionally substituted heterocyclic  
 group, or R<sup>2</sup> and R<sup>3</sup> may form an optionally substituted ring  
 together with an adjacent nitrogen atom, or a salt thereof.

2. The compound according to claim 1 which is a  
 compound represented by the formula



15 wherein Ring A'' represents a pyridine ring which may  
 have 1 to 3 substituents selected from a C<sub>1-4</sub> alkyl group

and a mono-, di- or tri-halogeno-C<sub>1-4</sub> alkyl group and other symbols are as defined in claim 1, or a salt thereof.

3. The compound according to claim 1, wherein X is a nitrile group.

5        4. The compound according to claim 1, wherein Y is -CH=CH- or -(CH<sub>2</sub>)<sub>2</sub>-.

5. The compound according to claim 1, wherein R<sup>1</sup> is (1) a C<sub>5-7</sub> cycloalkyl group optionally fused with a benzene ring, (2) a C<sub>7-19</sub> aralkyl group, (3) a 5- or 6-membered  
10 heterocyclic ring-C<sub>1-4</sub> alkyl group or (4) a C<sub>6-14</sub> aryloxy-C<sub>1-4</sub> alkyl group, each of which may have 1 to 4 substituents selected from a halogen atom, a C<sub>1-4</sub> alkyl group, a mono-, di- or tri-halogeno-C<sub>1-4</sub> alkyl group and a C<sub>1-4</sub> alkoxy group.

6. The compound according to claim 1, wherein one of  
15 R<sup>2</sup> and R<sup>3</sup> is a hydrogen atom or a C<sub>1-4</sub> alkyl group, and the other is a 5- or 6-membered heterocyclic group, a C<sub>6-14</sub> aryl group, a C<sub>7-19</sub> aralkyl group, a C<sub>3-10</sub> cycloalkyl group, a 5- or 6-membered heterocyclic ring-C<sub>1-4</sub> alkyl group or C<sub>1-6</sub> alkyl group, each of which may have 1 to 4 substituents  
20 selected from a halogen atom, a C<sub>1-4</sub> alkyl group, a mono-, di- or tri-halogeno-C<sub>1-4</sub> alkyl group, a C<sub>1-4</sub> alkoxy group, a C<sub>1-4</sub> alkoxy-carbonyl group, a cyano group, a C<sub>1-4</sub> alkyl-carbonylamino group and a hydroxy group; or R<sup>2</sup> and R<sup>3</sup>,  
25 together with an adjacent nitrogen atom, form a 5- or 6-membered nitrogen-containing heterocyclic ring optionally

containing 1 to 3 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom in addition to carbon atoms and one nitrogen atom, in which the nitrogen-containing heterocyclic ring may have 1 to 4 substituents selected from a halogen atom, a C<sub>1-4</sub> alkyl group, a mono-, di- or tri-halogeno-C<sub>1-4</sub> alkyl group, a C<sub>1-4</sub> alkoxy group and a C<sub>1-4</sub> alkoxy-carbonyl group.

7. (2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethoxyphenyl)prop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethylphenyl)prop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-methyl-N-phenylprop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3-methylphenyl)prop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(4-hydroxy-3-methoxyphenyl)prop-2-enamide, or salts thereof.

8. A prodrug of the compound according to claim 1.

9. A medicine comprising the compound according to

claim 1 or a prodrug thereof.

10. The medicine according to claim 9 which is a vanilloid receptor agonist.

5 11. The vanilloid receptor agonist according to claim 10 which is for local administration.

12. The vanilloid receptor agonist according to claim 10 which is an agent for preventing and/or treating overactive bladder.

10 13. The vanilloid receptor agonist according to claim 10 which is an analgesic.

14. A method of preventing and/or treating overactive bladder, comprising administering to a mammal in need an effective amount of the compound according to claim 1 or a prodrug thereof.

15 15. An analgesic method comprising administering to a mammal in need an effective amount of the compound according to claim 1 or a prodrug thereof.

20 16. Use of the compound according to claim 1 or a prodrug thereof for manufacturing an agent for preventing and/or treating overactive bladder.

17. Use of the compound according to claim 1 or a prodrug thereof for manufacturing an analgesic.